Comparative Pharmacology
Head-to-head clinical analysis: TARACTAN versus THIOTHIXENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TARACTAN versus THIOTHIXENE.
TARACTAN vs THIOTHIXENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the brain. It also has alpha-adrenergic and histamine H1 blocking activity, with minimal anticholinergic effects.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
Initial: 2 mg orally three times daily; maintenance: 5-30 mg/day orally in divided doses; maximum: 60 mg/day. IM: 4 mg 2-4 times daily; maximum 30 mg/day.
None Documented
None Documented
Clinical Note
moderateThiothixene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Thiothixene."
Clinical Note
moderateThiothixene + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Thiothixene is combined with Fluticasone propionate."
Clinical Note
moderateThiothixene + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Thiothixene."
Clinical Note
moderateTerminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Terminal half-life: 10-20 hours (mean ~14 h). Clinical context: Steady-state achieved in ~2-3 days; allows once-daily dosing for maintenance.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Primarily renal: 65-70% as metabolites, <1% unchanged. Fecal: 15-20% via biliary elimination.
Category C
Category C
Typical Antipsychotic
Typical Antipsychotic
Thiothixene + Methylphenidate
"The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate."